ESOU 2022 utilization of en bloc resection in non-muscle invasive bladder cancer (NMIBC), En bloc resection of bladder tumors, clinical trial comparing TURBT and en-bloc resection of bladder tumor.
Epigenetic Test May Rule Out High-Grade UTUC renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: KEYNOTE-564: Phase 3 Trial of Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma Discussion urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Share:
Data Includes First Real World Evidence on Alternating Bladder EpiCheck® and Cystoscopy for Surveillance of Non-Muscle Invasive Bladder Cancer (NMIBC)
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress.
The first abstract titled, Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance, shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance. To alleviate the burden of invasive and costly standard surveillance methods on patients, urine collection was performed at home and shipped to a central lab to perform the Bladder EpiCheck test. In the pi
Data Includes First Real World Evidence on Alternating Bladder EpiCheck® and Cystoscopy for Surveillance of Non-Muscle Invasive Bladder Cancer (NMIBC)
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress.
The first abstract titled, “Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance,” shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance. To alleviate the burden of invasive and costly standard surveillance methods on patients, urine collection was performed at home and shipped to a central lab to perform the Bladder EpiCheck test. In the pilot